Crispr Therapeutics Ag
CRSP
Biological Products, (No Diagnostic Substances)
Mkt Cap
$4.471BPE
-20.59Debt
-Cash
$707.4MEV
-FCF
-$166.6MP/E Ratio
-20.59Debt
-Cash
$707.4MEV
-FCF
-$166.6MCharts data: {"Earnings":[{"time":"2014-12-30","value":-7009000},{"time":"2015-12-30","value":-25828000},{"time":"2016-12-30","value":-23202000},{"time":"2017-12-30","value":-68357000},{"time":"2018-12-30","value":-164981000},{"time":"2019-12-30","value":66858000},{"time":"2020-12-30","value":-348865000},{"time":"2021-12-30","value":377661000},{"time":"2022-12-30","value":-650175000},{"time":"2023-12-30","value":-153610000}],"Sales":[{"time":"2015-12-30","value":247000},{"time":"2016-12-30","value":5164000},{"time":"2017-12-30","value":40997000},{"time":"2018-12-30","value":3124000},{"time":"2019-12-30","value":289590000},{"time":"2020-12-30","value":719000},{"time":"2021-12-30","value":914963000},{"time":"2022-12-30","value":1198000},{"time":"2023-12-30","value":371206000}],"Net Margins":[{"time":"2015-12-30","value":-104.56680161943319},{"time":"2016-12-30","value":-4.4930286599535245},{"time":"2017-12-30","value":-1.6673659048223042},{"time":"2018-12-30","value":-52.81081946222791},{"time":"2019-12-30","value":0.23087123174142754},{"time":"2020-12-30","value":-485.2086230876217},{"time":"2021-12-30","value":0.4127609531751557},{"time":"2022-12-30","value":-542.7170283806344},{"time":"2023-12-30","value":-0.41381335431000577}],"Assets":[{"time":"2015-12-30","value":159423000},{"time":"2016-12-30","value":344962000},{"time":"2017-12-30","value":271346000},{"time":"2018-12-30","value":489016000},{"time":"2019-12-30","value":1066752000},{"time":"2020-12-30","value":1827966000},{"time":"2021-12-30","value":2751877000},{"time":"2022-12-30","value":2243057000},{"time":"2023-12-30","value":2229571000}],"Stockholders Equity":[{"time":"2014-12-30","value":-6974000},{"time":"2015-12-30","value":-29097000},{"time":"2016-12-30","value":232846000},{"time":"2017-12-30","value":187832000},{"time":"2018-12-30","value":392195000},{"time":"2019-12-30","value":939425000},{"time":"2020-12-30","value":1664234000},{"time":"2021-12-30","value":2399460000},{"time":"2022-12-30","value":1875479000},{"time":"2023-12-30","value":1882803000}],"ROE":[{"time":"2014-12-30","value":1.0050186406653283},{"time":"2015-12-30","value":0.8876516479362133},{"time":"2016-12-30","value":-0.09964525909828814},{"time":"2017-12-30","value":-0.3639262745432088},{"time":"2018-12-30","value":-0.4206606407526868},{"time":"2019-12-30","value":0.07116906618410197},{"time":"2020-12-30","value":-0.20962496860417465},{"time":"2021-12-30","value":0.15739416368682954},{"time":"2022-12-30","value":-0.3466714370035602},{"time":"2023-12-30","value":-0.08158580584373405}],"ROA":[{"time":"2015-12-30","value":-0.16138825639964122},{"time":"2016-12-30","value":-0.06585652912494709},{"time":"2017-12-30","value":-0.23824932005631186},{"time":"2018-12-30","value":-0.3250261750126785},{"time":"2019-12-30","value":0.0630943274538037},{"time":"2020-12-30","value":-0.1904061672919518},{"time":"2021-12-30","value":0.13791713801161898},{"time":"2022-12-30","value":-0.29000600519737124},{"time":"2023-12-30","value":-0.06760134572973904}]}
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Sector
In the chart Earnings are multiplied by this value.
Earnings Growth 230%
Earnings Stability -36%
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | -10K% | -450% | -170% | -5.3K% | 23% | -49K% | 41% | -54K% | -41% | -80% |
| ROA | -16% | -6.6% | -24% | -33% | 6.3% | -19% | 14% | -29% | -6.8% | -8.8% |
| ROE | 89% | -10% | -36% | -42% | 7.1% | -21% | 16% | -35% | -8.2% | -10% |
What is the average Net Margin?
The average Net Margin over the past 5 years is -18.01K%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is -2.52K%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is -11.2%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is +1.59%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is -13.83%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is +2.31%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | - | - | - | - | - | - | - | - | - | - |
| Debt Equity | -1.32 | - | - | - | - | - | - | - | - | - |
| MIN | ||||||||||
| Graham Stability | - | - | - | - | - | - | - | -2K% | - | -2K% |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is -.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is -.
What is the Graham’s Stability?
Graham’s Stability measure stands at -20.39.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | 84% | 160% | 700% | 31K% | 6.8K% |
| Net Income | - | - | - | - | - |
| Stockholders Equity | 35% | 37% | 4.2% | 0.39% | -11% |
| FCF | - | - | - | - | - |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is +160%.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is +6.79K%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is -1.42%.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is -.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is +36.85%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is -10.62%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is +22.2%.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -.